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Abstract
Objective: The main objective of this study was to assess the quality of home malaria management
with pre-packaged chloroquine in two areas in the Moramanga district of Madagascar. The
knowledge, attitude and practices of care providers in terms of home treatment options were
evaluated and compared. The availability of treatment options by studying retailers and community-
based service providers was also investigated.
Methods: A cross-sectional investigation in two communities, in the hamlets and villages located
close to carers, retailers, community-based service providers and primary health centres was
carried out.
Results: Carers in the two districts were equally well aware of the use of pre-packaged
chloroquine. Their first response to the onset of fever was to treat children with this antimalarial
drug at home. The dose administered and treatment compliance were entirely satisfactory (100%)
with pre-packaged chloroquine and rarely satisfactory (1.6% to 4.5%) with non pre-packaged
chloroquine. In cases of treatment failure, the carers took patients to health centres. Chloroquine
was supplied principally by private pharmacies and travelling salesmen selling unpackaged
chloroquine tablets. Non pre-packaged chloroquine was the most common drug used at health
centres. The frequency of positive rapid malaria tests (P = 0.01) was significantly higher in children
treated with non pre-packaged chloroquine (38%) than in children treated with pre-packaged
chloroquine (1.3%).
Conclusion: Home malaria management should be improved in Madagascar. Efforts should focus
on communication, the training of community-based service providers, access to pre-packaged
drugs and the gradual withdrawal of pre-packaged chloroquine and its replacement by pre-
packaged artemisinin-based combination therapies.
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Malaria, known locally as "tazo" or "tazomoka", is the lead-
ing cause of morbidity, mortality and hospital admission
in Madagascar. Official data show a reported 2,114,400
cases of suspected malaria in 2003 (18.8% of all outpa-
tient visits). About 740,000 of these cases occurred in chil-
dren under the age of five years [1-3]. Limited physical
access to public health facilities has been recognized to
limit the provision of early treatment in developing coun-
tries, such as Madagascar. As a result of this limited access,
communities resort to self-medication, through the
unregulated private and informal sectors [4-6]. Thus,
pharmacies, medicine shops or vendors, retail shops and
medicines left over in homes are often the first source of
treatment when symptoms begin [7]. As most of the chil-
dren who die from malaria do so within 48 hours of the
onset of illness, the early use of effective antimalarial med-
icines in or near the home can reduce the burden of
malaria in endemic areas. This acknowledged time ele-
ment is critical for saving children's lives in Africa and for
reducing severe malaria morbidity and mortality in non-
immune older children and adults living in other regions
of the world [8,9]. A strong health care-delivery system
should ideally provide early, reliable diagnosis and appro-
priate, prompt and effective treatment. However, most of
those at highest risk of malaria in Madagascar live in rural
areas geographically distant from health facilities (40% of
people live more than five kilometres away from the near-
est health facility, including 27% more than 10 kilometres
away from the nearest health facility).
In 1989, Malagasy health policy-makers decided to rec-
ommend a strategy based on the home management of
malaria (HMM). This decision followed a major malaria
outbreak in the mid-1980s, with the widespread distribu-
tion of chloroquine (in the form of unpackaged 100 mg
tablets). HMM was advocated as part of the National
Malaria Control Programme (NMCP) in 1998. In Novem-
ber 2003, pre-packaged (PaluStop®) was introduced pri-
vately by an NGO called "Population Service
International" and sold at an affordable price of US
$0.025. Since March 2005, another form of pre-packaged
chloroquine, Ody Tazomoka®, has been freely distributed
at primary public health facilities. Both presentations of
pre-packaged chloroquine are available for children from
six to 11 months of age (three tablets of 75 mg) and for
children from 12 to 59 months of age (three tablets of 150
mg) (Figure 1).
The main objective of this study was to assess the quality
of HMM implementation with pre-packaged chloroquine,
in two areas of the Moramanga district of Madagascar (in
the periurban community of Ambohibary and in the
remote rural community of Lakato). The knowledge, atti-
tude and practices of caregivers in terms of home treat-
ment options (non pre-packaged and pre-packaged
chloroquine) were first evaluated and compared, at com-
munity level, by interviewing carers, and at primary health
centre level, by interviewing the parents or guardians of
children under the age of five years consulting for fever.
The malaria burden among these children was also evalu-
ated by rapid testing. The availability of treatment options
in these two areas, by studying retailers and community-
based service providers was also investigated.
Materials and methods
Study areas and setting
This survey was conducted between April and June 2005,
in two communities in the eastern foothills of the high-
lands of Madagascar: Ambohibary, a periurban commu-
nity, and Lakato, a remote rural community (Figure 2).
Lakato (19°11'53.7" S, 48°23'32.6" E), is located in a
remote area 40 kilometres away from the national road
connecting Antananarivo, the capital of Madagascar, to
Toamasina, the main harbour on the east coast. This area
is poorly accessible, especially at the beginning of the
study period (rainy season), and can only be reached by
poor-quality tracks. It covers an area of 702 km2 (altitude
of 295 to 1,040 metres), with 15,831 inhabitants, living in
10 villages, with 44 hamlets. There is one "level two" pri-
mary health centre (CSB2: "centre de santé de base niveau
2", managed by a physician) and two "level one" primary
health centres (CSB1: "centre de santé de base niveau 1"
managed by a nurse). The prevalence of malaria in chil-
dren under five years of age in this district has been esti-
mated at 30%, with peaks in April-May and September-
October (Malagasy Ministère de l'Intérieur et Collectivité ter-
ritoriale for the district of Moramanga, 2005).
Ambohibary (18°54'55.5" S, 48°13'39.3" E) is located in
a periurban area seven kilometres from the urban centre
of Moramanga. It covers an area of 729 km2 (altitude of
910 to 1,040 metres), with 16,557 inhabitants living in
nine villages with 50 hamlets. It has one level 2 primary
health centre and two level 1 primary health centres. The
prevalence of malaria in children under five years of age in
this district has been estimated at 27%, with a peak in
April-May (data from the Malagasy Ministère de l'Intérieur
et Collectivité for the district of Moramanga, 2005).
Sampling methods and data collection
A cross-sectional investigation in the two communities,
focusing on carers, drug sellers and community-based
service providers and primary health centres in the ham-
lets and villages was carried out.
A two-level cluster sampling for the investigation of carers
was used. A questionnaire was designed to collect data on
knowledge, attitudes, practices and beliefs (KAPB) relat-Page 2 of 8
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to determine the frequency of knowledge relating to
HMM. The minimum sample size required for the carer
investigation was estimated at 392 (with 95% confidence
intervals). Four hundred twenty carers (30 clusters of 14
carers) were finally included. All villages were informed
one day before the investigation, by the head of the dis-
trict. Each interviewer worked with a guide, who intro-
duced him at each village. On the day of the investigation,
the objectives of the study were explained to the children's
carers before the interview. Carers were included in the
study after they provided written informed consent. Dur-
ing the investigation, the interviewers were provided with
questionnaires and pre-packaged chloroquine (PaluStop®
and Ody Tazomoka®). If the carers said that they had used
pre-packaged chloroquine, they were asked to indicate the
presentation used: PaluStop® or Ody Tazomoka®. The
investigator also checked whether insecticide-impreg-
nated bed nets were used.
In Ambohibary and Lakato, all drug retailers and commu-
nity-based service providers were interviewed with a
designed questionnaire, after they had given written
informed consent.
At primary health centres (three in Ambohibary and three
in Lakato), all children under the age of five, clinically sus-
pected of malaria (fever and recent history of fever) were
enrolled and their parents or guardians were interviewed
after they had provided written informed consent. Ques-
tionnaires were completed by health workers. The investi-
gator carried out a rapid diagnostic test (OptiMal-IT®,
DiaMed, Switzerland) to confirm the diagnosis of malaria
and checked that the questionnaire had been completed
Pre-packaged chloroquine (PaluStop® and Ody Tazomoka®) used for HMM in Madagascar (green boxes: for children aged 6 to 11 months, 3 pil s of 75 mg, and blue boxes: for children from 12 t  59 months, 3 pill  of 150 mg)Figure 1
Pre-packaged chloroquine (PaluStop® and Ody Tazomoka®) used for HMM in Madagascar (green boxes: for children aged 6 to 
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communicated to the head of the primary health centre.
Data analysis
Data were entered, processed and analysed with EpiInfo
software (CDC, version 3.3.2). Chi-squared tests were
used to assess the significant of differences between pro-
portions. For continuous data, the significance of differ-
ences was assessed using Student's t-tests or Kruskal-
Wallis tests.
Results
The study was carried out in 27 hamlets and villages (13
in Ambohibary and 14 in Lakato). At the community
level, 420 carers (196 in Ambohibary and 224 in Lakato),
10 community-based service providers (6 in Ambohibary
and 4 in Lakato) and 32 retailers (22 in Ambohibary and
10 in Lakato) were interviewed. At primary health centre
level, 341 patients attended health centres (109 in Ambo-
hibary and 232 in Lakato), of which 207 children under
the age of five, clinically suspected of malaria, were
enrolled in the study (60 in Ambohibary and 147 in
Lakato).
Investigation of carers
More than 95% of the 420 carers interviewed were the
mothers of the patients concerned. The youngest carer was
15 years old, the oldest was 65 years old and the median
age of the carers was 29 years. Three-quarters (79.1% in
Ambohibary and 69.2% in Lakato) of carers were married,
or cohabited with a partner, the remaining carers being
single, divorced, separated or widowed. The mean
number of children under the age of five years looked
after by an individual carer was significantly higher in
Lakato (1.6) than in Ambohibary (1.4) (P = 0.0026). Sig-
nificant differences were also found between the two dis-
tricts in terms of professional activity (P < 10-6): 90.6%
farmers in Lakato and 54.6% farmers in Ambohibary,
with 19.4% craftsmen in Ambohibary and 0.4% in
Lakato. Educational status profiles also differed signifi-
cantly between Ambohibary and Lakato (P = 0.00005): no
formal education (15.3% in Ambohibary and 42% in
Lakato), primary education (51.5% in Ambohibary and
39.3% in Lakato), and secondary or further education
(33.1% in Ambohibary and 18.8% in Lakato). The dis-
tance from the hamlet or village to the nearest health cen-
tre also differed significantly (P < 10-6) between
Ambohibary and Lakato (Table 1). More than two-thirds
of the carers in Ambohibary lived less than two hours
walk from the nearest health centre, whereas more than
two-thirds of the carers in Lakato lived more than two
hours walk from the nearest health centre.
The carers' knowledge about malaria was assessed (Table
2). Carers in Ambohibary were significantly better
informed about malaria transmission than their counter-
parts in Lakato. In Ambohibary, carers were as familiar
with PaluStop® as with Ody Tazomoka®, whereas carers in
Lakato were more familiar with PaluStop®, because this
form of pre-packaged chloroquine was distributed freely
in this area by and NGO.
The management of uncomplicated childhood fever by
carers in Ambohibary and Lakato is detailed in Table 3. In
most cases, carers in both areas initially reacted to the
onset of fever by treating the child with an antimalarial
drug at home. However, in the rural area of Lakato, tradi-
tional treatment was widespread and used by more than
one quarter of carers (bitter plants such as Exacum sp, from
the Gentianaceae family, known as "felatanandraka" or
"aferontany" in Malagasy). In most cases, the plant con-
cerned was gathered, prepared and administered directly
by the carer. The reasons for administering antimalarial
drugs at home, according to carers, differed slightly
between the two areas: (i) in Ambohibary, the first reason
given by carers was that they already had such drugs at
home (46.8% non pre-packaged chloroquine and 53.2%
pre-packaged chloroquine), the second reason was that
they had enough money to pay for a consultation with a
Map of the Moramanga District (with primary health centres)Figure 2
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centre was too far away; (ii) in Lakato, the two most
important reasons given by carers were that they already
had drugs at home (42.8% non pre-packaged chloroquine
and 57.2% pre-packaged chloroquine), and the health
centre being too far away. The third reason given was that
there were often no health workers at the health centre.
Regardless of the location, it was observed that the further
the distance between the village and the health centre, the
more likely the carer was to use antimalarial drugs at
home (at Ambohibary, 66% for carers less than one hour
from the health centre and 86% more than one hour from
the health centre used antimalarial drugs at home; at
Lakato, 83% of carers living less than one hour from the
health centre and 97% living more than one hour from
the health centre used antimalarial drugs at home). Con-
versely, the frequentation of health centres decreased with
distance from the village, from 34% to 13% in Ambo-
hibary and from 17% to 3% in Lakato.
In both areas, the dose administered and treatment com-
pliance were entirely satisfactory (100%) with pre-pack-
aged chloroquine treatment (PaluStop® or Ody
Tazomoka® )and rarely satisfactory (1.6% to 4.5%) with
non pre-packaged chloroquine treatment. The carers took
a mean time of 3.5 days (3.7 in Ambohibary and 3.3 in
Lakato) to evaluate the efficacy of treatment. In case of
treatment failure (persistence of malaria symptoms), the
carers in both communities took the patient to a health
centre.
Investigations of retailers and community-based service 
providers
Chloroquine was supplied principally by private pharma-
cies and travelling salesmen in the two areas. In the per-
iurban area of Ambohibary and in the remote area of
Lakato, health workers were responsible for educating car-
ers, providing them with sufficient information to enable
them to recognize the clinical symptoms of malaria, to
assess its severity and to take appropriate action.
Unpackaged chloroquine tablets were sold more fre-
quently than pre-packaged chloroquine tablets to carers
by retailers and salesmen. The carers often bought an
Table 2: Carers' knowledge about malaria in the Ambohibary and Lakato areas (District of Moramanga, Madagascar)
Areas
Variable Results Ambohibary Lakato P <chi 2>
No (%) No (%)
Recorded symptoms Fever alone or in combination with others 
symptom*
195 (99.5) 223 (99.5) NS
Knowledge of malaria transmission By mosquitoes 144 (73.5) 73 (32.6) < 10 -4
By other ways 23 (11.7) 23 (10.3) NS
None 29 (14.8) 128 (57.1) < 10 -3
Malaria prevention used for children under 
5 years
Chloroquine 3 (1.5) 3 (1.3) NS
Impregnated bed nets 63 (35.2) 78 (34.8) NS
None 124 (63.2) 143 (63.8) NS
Knowledge of the use of pre-packaged 
chloroquine
PaluStop® 140 (71.4) 171 (76.1) NS
Ody Tazomoka® 137 (69.9) 65 (29.0) < 10 -6
*Sweating, red eyes, shivering, joint pain, dizziness, cough, diarrhoea, runny nose, anorexia, vomiting
Table 1: The distances (walking times) between the villages and hamlets and the nearest health centre in the Ambohibary and Lakato 
areas (District of Moramanga, Madagascar)
Areas
Distance between the villages and the nearest health 
centre (in time)
Ambohibary n = 196 % (CI95%) Lakato n = 224 % (CI95%) P <chi 2>
0 to 30 minutes 29.1 (22.8–36) 11.6 (7.7–16.5) < 10-6
30 to 60 minutes 35.7 (29–42.9) 4.5 (2.2–8.1)
1 to 2 hours 13.8 (9.3–19.4) 7.1 (4.1–11.3)
2 to 3 hours 20.9 (15.4–27.3) 40.2 (33.7–46.9)
3 to 4 hours 0 (0–1.9) 14.3 (10–19.6)
More than 4 hours 0.5 (0–2.8) 22.3 (17–28.3)Page 5 of 8
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tablets in Ambohibary and two to three 100 mg tablets in
Lakato). A single tablet of 100 mg non pre-packaged chlo-
roquine was sold at the same price as an entire box of pre-
packaged chloroquine (full treatment for a child under
five). Chloroquine often seemed to be in short supply in
both areas.
Four retailers and salesmen in Ambohibary (18%) and
two retailers in Lakato (20%) sold pre-packaged chloro-
quine (PaluStop®). This brand of chloroquine has been
available for 12 months in Ambohibary and 10 months in
Lakato.
Ody Tazomoka® was distributed freely by the six commu-
nity-based service providers in Ambohibary (100%) and
by only one such service provider in Lakato (25%). This
drug only became available a few weeks before the start of
the study.
Primary health centre investigations
Of the 207 children under five years of age seen at health
centres (60 in Ambohibary and 147 in Lakato), 50% were
initially treated at home in Ambohibary and 27.2% in
Lakato. The mean time between the onset of fever and
consultation at a health centre was two days in Ambo-
hibary (0 to 6 days) and three days in Lakato (0 to 14
days).
In both areas, non pre-packaged chloroquine was the drug
most frequently used for treatment at home (53.7% in
Ambohibary and 50.8% in Lakato). Pre-packaged chloro-
quine was used less frequently (19.6% in Ambohibary
and 10.4% in Lakato). Of the 70 children treated with
chloroquine at home, 55 were treated with non pre-pack-
aged chloroquine and 15, with pre-packaged chloroquine.
Rapid tests for malaria were positive in 40% of cases in
Ambohibary and 45% of cases in Lakato. The frequency of
positive rapid tests for malaria (P = 0.01) was significantly
higher for children treated with non pre-packaged chloro-
quine (38% positive rapid tests overall, 18% in Ambo-
hibary and 52% in Lakato) than for children treated with
pre-packaged chloroquine (1.3% positive rapid tests over-
all, 2% in Ambohibary and 0% in Lakato).
Discussion
The success of health interventions such as HMM requires
communities to have detailed knowledge of perceived
Table 3: Carer's management of uncomplicated childhood fever in the Ambohibary and Lakato areas (District of Moramanga, 
Madagascar)
Areas
Variable Results Ambohibary Lakato P <chi 2>
No (%) No (%)
Action of the carer at fever onset Went to clinic/health centre 52 (26.5) 24 (10.7) < 10 -5
Used antimalarial drugs at home (self-treatment) 139 (70.9) 138 (61.6) 0.05
Used herbal medicines 5 (2.5) 57 (25.4) < 10 -6
Went to traditional healer 0 (0) 5 (2.2) NS
Reasons given by carers for use of 
antimalarial drugs at home
No health worker at health centre 0 (0) 46 (20.5) < 10 -6
No money to pay for consultation 51 (25.7) 31 (13.8) 0.002
Long distance to health centre 29 (14.6) 73 (32.8) < 10 -4
Correct treatment known/Drugs already at home 117 (59.7) 74 (32.9) < 10 -6
Antimalarial drugs used at home Not pre-packaged chloroquine 65 (46.8) 59 (42.8) NS
PaluStop® 50 (36.0) 2 (1.4) NS
Ody Tazomoka® 24 (17.2) 77 (55.8) 0.007
Correct dose of chloroquine administered by 
carer
Non pre-packaged chloroquine 1 (1.5) 1 (1.6) NS
PaluStop® 50 (100) 2 (100) NS
Ody Tazomoka® 24 (100) 77 (100) NS
Action after treatment failure Went to community-based service provider 7 (3.6) 24 (11) NS
Went to clinic/health centre 186 (94.9) 164 (73.0) < 10 -6
Used herbal medicines 0 (0) 6 (3.0) -
Went to traditional healer 3 (1.5) 30 (13.0) NSPage 6 of 8
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recognized as amenable to modern health interventions if
their manifestations are perceived as being amenable to
modern treatment [11]. In Ambohibary and Lakato,
malaria is the most common health problem in child-
hood. The prevalence of malaria in children under the age
of five in the health centres of these two areas is similar to
national estimates [2]. Thus, these communities are will-
ing to participate in health interventions aiming to reduce
the frequency of malaria in their children.
This study was carried out in two areas with different
socio-demographic profiles, representative of the current
situation in Madagascar. In these two areas, most of the
carers were mothers, as reported in other areas of Mada-
gascar [11] and in Africa [12,13]. The mother's ability to
associate malaria with fever has important implications
for the survival of her child in areas of endemic malaria
[14,15]. In Ambohibary as well in Lakato, investigation of
carers showed 99.5% of them identified malaria as fever
alone or in combination with other symptoms such as
sweating, red eyes, shivering, headache, joint pain, dizzi-
ness, cough, diarrhoea, runny nose, anorexia or vomiting.
This frequency is higher than that reported in other stud-
ies: 85.6% in the Democratic Republic of Congo [16] and
80.8% in Burkina Faso [17].
In the two areas studied, mothers faced with a case of sus-
pected malaria in one of their children chose first to
administer antimalarial drugs at home, seeking care for
their child at a health facility only in case of treatment fail-
ure. This shows that mothers have the potential to manage
malarial fever correctly at home and to consult health
workers. These positive attitudes and practices should be
reinforced during health interventions, to decrease severe
morbidity and mortality from childhood malaria by
improving case management. However, even in Ambo-
hibary, where the mothers knew that malaria was trans-
mitted by mosquitoes, only one third of the children slept
under insecticide-impregnated bed nets. Although many
mothers were aware of pre-packaged chloroquine (69.9%
in Lakato and 76.1% in Ambohibary) only half of them
used it, often because they had the drug in an non-pack-
aged form at home. This was the case in the periurban area
of Ambohibary, where the flow of information about
HMM strategy and the supply of pre-packaged chloro-
quine are easy to establish. In this area, either information
about the HMM strategy was not transmitted by health
workers due to a lack of motivation, or carers chose not to
use the free pre-packed chloroquine because they thought
that it was not effective. In the remote area of Lakato, the
main reason for not using pre-packaged chloroquine was
the time lag to the release of free pre-packaged chloro-
quine, because of a lack of co-ordination between the
communities and the headquarters of the district health
authority.
Chloroquine was introduced into Madagascar in 1945
and is the antimalarial drug best known to the Malagasy
people [18,19]. As previously reported in Madagascar [11]
and Nigeria [20], non pre-packaged tablets were not used
appropriately in either Ambohibary or Lakato. In these
two areas, the use of non pre-packaged chloroquine by
carers led to a significantly higher rate of treatment failure,
as shown in this study for health centre-based analyses. By
contrast, all carers using pre-packaged chloroquine used
this drug at the correct dose. For HMM to be effective, the
population must be aware of: (i) the correct dose and (ii)
the need to complete treatment (drug resistance often
develops because the course of treatment is not com-
pleted). The easy-to-follow leaflet, with illustrations on
the box and the blister-packed tablets may also have
encouraged carers to use pre-packaged chloroquine. Simi-
larly, in Uganda [21], mothers favoured pre-packaged
chloroquine, known as "homapak", because it was neatly
and attractively packaged. A decrease in the efficacy of
chloroquine against P. falciparum has recently been
recorded in several areas [22,23]. Based on these findings,
the Malagasy Ministry of Health could improve HMM by
withdrawing pre-packaged chloroquine, gradually replac-
ing it with pre-packaged artemisinin-based combination
therapies (ACT, such as artesunate plus amodiaquine, the
first-line treatment recommended for uncomplicated
malaria in Madagascar in the forthcoming revised
national policy. ACT acts more rapidly, has a higher cure
rate and causes fewer side-effects than other treatment,
such as chloroquine, but is more expensive.
However, if pre-packaged drugs are to be used, efforts are
required: (i) to ensure effective communication, favour-
ing correct care-seeking behaviour and appropriate and
effective HMM for the treatment of febrile illness. Particu-
lar attention should be paid to stressing the link between
mosquitoes and malaria for less literate carers, and the
importance of prompt and complete treatment with pre-
packaged drugs; (ii) to train community-based service
providers, to ensure that they have the necessary skills and
knowledge to manage febrile illness or malaria. This train-
ing could take place within the commercial sector, but
might then have to be based on a limited curriculum, dic-
tated by the amount of time that trainers are willing to
spend without compromising their own businesses; (iii)
to supervise and monitor implementation activities at the
community and health facility levels.
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